Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2743 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-04-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Before Alzheimer's disease (AD) clinical symptoms appear, there is a long period when changes in the brain occur. In this long asymptomatic period or preclinical phase, studies with populations at risk of developing AD have shown cognitive differences compared to control groups without such risk. There is a need for short, sensitive, easily administered, reproducible, non-expensive and independent of socio-demographic influences tests enabling the detection of pre-symptomatic variations in memory, when the memory decline is still within a normal range.

Study main hypothesis: When evaluated with high-demanding tests of memory and executive function, the cognitive performance of cognitive healthy people aged between 45 and 65 and, extensively, to a group of up to 75 years, will vary significantly depending on clinical, socio-demographic and genetic features

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Brain Function During Cognitive Tasks

NCT00076739

Healthy

COMPLETED

Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes

NCT01867372

Alzheimer's Disease

TERMINATED

Normative QEEG/ERP Data for Healthy Volunteers

NCT05869032

Healthy

RECRUITING

Imaging of New Learning in Severe Alzheimer's Disease Patients

NCT01839422

Alzheimer Disease

UNKNOWN NA

Development and Decline of Brain and Cognition Through the Life Span

NCT00880451

Alzheimer's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of Study 45-65 is to assess if:

* Endogenous factors (clinical history, risk factors, genetic factors APOE4, etc…), exogenous (socio-demographic, ambient and lifestyle variables) and cognitive reserve (including bilingualism) influence cognitive performance.
* New and/or updated tests translated and validated in Spanish and Catalan when needed, will provide accurate and sensitive measurements of the variability of cognitive performance in this target population, representative of the preclinical phase of Alzheimer's disease.

An optional visit is offered to study participants that includes: cerebral magnetic resonance, vascular ultrasound and olfactory testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Individuals

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cognitively normal individuals

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women, aged between 45 and 75 years
2. Spanish and/or Catalan speakers
3. Agreement with the study procedures and tests:

1. Clinical Interview and questionnaires associated to risk factors
2. Cognitive tests
3. Blood sample extraction for DNA analysis
4. Close relative involvement for functional evaluation of the volunteer
5. Signature of informed consent

Exclusion Criteria

1. Cognitive impairment: MMSE \<26, o MIS \<6, or orientation subtest of the Barcelona Test II \<68, o category fluency (animals) \<12
2. Functional status impairment: CDR \> 0
3. Severe auditory and/or visual impairment
4. Neurodevelopmental and/or psychomotor disorder
5. Significant diseases that could currently interfere with cognition: renal failure on hemodialysis, liver cirrhosis, chronic lung disease with oxygen therapy, solid organ transplantation, fibromyalgia, active cancer in treatment or any other disease the investigator considers could affect the participant cognition
6. Major psychiatric disorders (DSM-IV-TR) or diseases that could affect cognitive abilities: major depression, bipolar disorder, schizophrenia and dementia.
7. Neurological disorders: Parkinson's disease, stroke, epilepsy and treatment with frequent seizures (\> 1/month) in the past year, multiple sclerosis or other serious neurological disease.
8. Brain injury interfering with cognition: history of head trauma with parenchymal lesion or extraaxial macroscopic large vessel ischemic stroke or hemorrhagic stroke, brain surgery, brain tumors and other causes that can generate acquired brain damage (cerebral chemotherapy or radiotherapy)
9. Family history of Alzheimer's disease with autosomal dominant (3 affected in two different generations) and early onset age (\<60 years).

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes